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ABSTRACT
THE RELATIONSHIP BETWEEN DIRECT TO CONSUMER MARKETING AND THE SELFPERCEPTION OF GERD SYMPTOMS IN THE YOUNG ADULT POPULATION
Sheila Kumar (Sponsored by Priya Jamidar). Division of Digestive Diseases, Department of Internal
Medicine, Yale University School of Medicine. New Haven, CT.
The purpose of this study was to determine the prevalence of gastroesophageal reflux d isease
(GERD) symptoms in a young adult population of university students and to examine the relationship
between direct-la-consumer marketing and the self-perception ofGERD symptoms.
GERO is defined as the spectrum of disease usually producing symptoms of heartburn and
ac id regurg itation. Previous studies have varied prevalences in the adult population ranging from 5%
to 45%, depending on the method of diagnosis. However, very little is known about the prevalence of
GERD in the young adult population. Proton pump inhibitors (PPIs) are widely utilized to control
GERD symptoms, and have been available without a prescription since 2003. During this time period,
the use of direct-to-consumer (DTC) marketing of prescription medications was permitted in the
United States. The prevalence or GERO in the young adul t population, as wel l as the impact of OTC
advertising on the self-reporting of GERO symptoms, is largely unknown.
A group-adm inistered questionnaire of 168 graduate and undergraduate students at Yale
University was performed between September 2006 and December 2006. The mean age of
respondents was 22.26 years. 68.64% of respondents were female. When using a diagnostic
. qualification of mild symptoms at least one day a week, 3.57% of the subject popu lation reported
heartburn symptoms, 8.92% reported regurgitation symptoms, and 1.79% reported both heartburn and
regurgitation symptoms. 92.3% of respondents reported exposure to DTC ads, with 89.83% of
respondents exposed to PP J advertisements. There was no correlation between exposure to
advertisements for heartburn/reflux medications and the self-reporting ofGERD symptoms.
The prevalence ofGERD symptoms in thi s young adult population is lower than that reported
in adult populations. Direct-la-consumer marketing does not appear to influence the way this
population perceives GERD symptoms.
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Introduction
Gastroesophageal reflux is defined as the movement of gastric contents from the stomach
to the esophagus, and GERD (gastroesophageal reflux) is defined as the spectrum of disease

usually producing symptoms of heartburn and acid regurgitation (I ).

PATHOPHYSIOLOGY
Reflu x occurs when acidic stomach contents contact with the esophagu s. The arrival of a
bolus offeod in the stomach causes distension and mucosa l irritat ion of the stomach epitheli um .
Th is leads to the secret ion of p rotons by proton pumps (H+IK+ ATP-ase) in the parieta l cells.

Histamine, gastrin, and acetylcholine regulate the activity of these pumps. Refl ux occurs
transiently in the normal patient, but is generally prevented by a three-stage system.
The first component of this system is the anatom ical anti-reflux barrier. The lower
esophageal sphincter (LES), a 3-4 cm long section of tonically contracted esophagus, generates
pressure between 10-30 mm Hg above the intragastric pressure in order to prevent the reflux of
gastric contents bac k into the esophagus (2). The pressure generated by the LES is affected by
several factors- for examp le, the presence of protein or honnones such as gastrin cause an
increase in the pressure, while the presence o f fat or honnones such as secretin cause a decrease
in the pressure. Diurnal variatio n also exists, such that the LES pressure is highest at night and
lowest after meals (J). Transient LES relaxation occurs in nonna l subjects during swa llowing and
belching, to a llow for the passage of food and a ir (3). In addition to the pressure generated by the
LES, further protection is afforded by the crura l diaphragm which surrounds the proxima l end of
the LES. The .crural diaphragm exerts an additional pressure to compensate when LES pressure is
not enough to prevent reflux.
The second mechanism to prevent reflux is esophageal acid clearance . The first
compo nent of this is volume clearance, or the actual c learance of gastric contents from the
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esophagus. Thi s occurs through two waves ofperistai sis. The first wave of peristalsis is initiated
by swallowing, while the second wave of peristalsis is initiated by the esophageal distension fro m

reflux. This second wave thus plays a less beneficial role than the initia l peristalsis. Volume
clearance is enhanced by gravity, which assists with bolus clearance through peristalsis. The
second component of this anti-reflu x mechanism is actual acid clearance, which refers to the
titration of acidic esophageal contents to a neutral level by the addition of a base. Saliva plays an
important role in this, as it functions as a weak base. The esophagosaJivary reflex, w hich refers to
the production of saliva after the majority of a bolus has been cleared through volume clearance,
results in the addition of this weak base to the remaining acidic esophageal contents (4).
The third tier of mechanisms to prevent reflu x is tissue resistance. This consists of preep ith e lia l, ep ith e li a l, a nd post-epithelia l sys t ems. The pre-e p it he li a l system does
not offer mu ch protection aga in st acidic co nt en ts in the esophagus, as cells in
thi s laye r ca nn o t secrete any buffer (in con tras t t o ce ll s found in this layer in
the s t omac h , for exam pl e, which c an sec r ete bicarbo nate). The ep ith e lial layer
offers pro t ec ti on through a thick layer of non -ke r atin ized s qu a mo u s ep ith e lium
con n ected t houg h numerous ti ght ju nc ti ons, that serves as an anatomic barrier
th roug h whi ch acid ic io n s ca nn ot pass. In a ddition , th e ce ll s in this layer secrete
severa l buffers . Bicarbonate is secr ete d through a sOd ium - ind epend e nt chlor id ebi carbo nate exchanger. Phosphate and negative ly c ha rged prot e in s a r e a lso
secreted. The ce ll s in thi s layer al so h ave th e abil it y to ac ti ve ly r e m ove pr oto n s,
throug h the act ions of a sod iu m-p r o t o n exchange r a nd a sodiu m-dependent
c h lo rid e-bicarbonate exchange r (5,6). The post -epithe li a l laye r offe r s protectio n
throug h the effects of esop h agea l bl ood flow , whi c h removes protons from a nd
ca rri es bi ca rb o n ate t o th e esop ha gus.
In gastro-esophageal reflu x, sevt:ral or all of these intrinsic anti-reflux mechani sms may
fail. In tenns of the anatomical anti-reflux barrier, transient relaxations of the LES occur nonna lly
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during swallowing and belching. as explained above; the role of these relaxations in GERD is
controversia l. Whether they are experienced more often by patients with GERD remains unclear,
with research supporting as well as challenging that theory (7). However, the probability of reflux
episodes during episodes of transient relaxation is greater in patients with GERD than in nonnal
patients (7). Stress reflux and free reflux are types of gastroesophageal reflux that are associated
with lowered LES pressures. In stress reflux, a sudden increase in intrabdom inal pressure from
coughing or straining overcomes an initially lowered LES pressure, and thus results in reflux.
Free reflu x occurs w hen there is no change in intra-abdominal pressure, yet reflux still occurs,
and is usually associated with an already lowered LES pressure (1).
Failures ·of esophageal ac id clearance can be due to failures of volume clearance or acid
clearance. One mechanism that may contribute to a failure of volume c learance is related to
esophagitis. It has been noted that patients with severe esophagitis have a higher prevalence of
peristaltic dysfunction that patients with mild esophagitis (8). As esophagitis is correlated with
reflux, it may be that reflux causes the increased peristaltic dysfunction, which then cycles back
to cause an increasing amount of reflu x. Or it may be that these pat ients have an innate peristaltic
dysfunction that then predisposes the m to esophagitis and reflux. 1t is worthwhile to mention
again the role that gravity plays in bolus vo lu me clearance to the stomach-thus, the initial
therapy for GERD that involves raising the head of the bed and the avoidance of lying sup ine
after meals all draw upon grav ity for their effi cacy. Failures of acid clearance may be secondary
to a decreased esophagosalivary reflex, which has been demonstrated in patients with reflux
esophagit is (9).

CLINICAL SYMPTOMS
Reflux has a wide spectrum of clinical symptoms. Patients commonly experience
heartburn, acid regurgitation, and dysphagia. Heartburn is retrostemal burning discomfort, that
radiates toward the neck, and is generally experienced postprandially. This sensation may be
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exacerbated by recumbency, bending over, large meals, spicy foods, chocolates, alcohol, and
citrus products (1). Dysphagia is reported by more than 30% of patients with GERO (10). This
symptom may be secondary to esophageal peristalsis or heightened esophageal sensitivity. When
associated with bolus impaction, it may be due to a peptic stricture, Schatski ring, esophageal
inflammation, or esophageal cancer (1,11). Water brash (hypersalivation) may occur, due to a
sudden increase in salivary production secondary to increased esophageal acidity. Odynophagia,
se<:ondary to increased sensitivity of the esophageal mucosa, may occur, and is usually associated
with severe esophagitis. Belching, hiccups, nausea, vomiting, and globus (constant perception of
a lump in throat) may be experienced (10.12). Extraesophageal symptoms include chest pain that
is similar in its characteristics to angina pectoris (1). Patients may also experience posterior
laryngitis, though whether re flux itself is the spec ific cause is unknown ( 10). Finally, patients
may experience

reflux~induced

asthma (13).

Barrett's esophagus is a known complication ofG ERD. This conditio n occurs w hen
columnar epithelium rep laces the nonnal squamous epithelium of the esophagus, and has been
hi storically associated w ith an increased risk of esophageal adenocarcinoma (14). However,
recent studies have questioned the incidence of increased risk of adenocarcinoma in patients with
Barrett's esophagus ( 15).

I?IAGNOS IS
The diagnosis ofGERD is often made on a c linical bas is. Initia l therapy usually involves
lifestyle interventions, which include elevation of the head of the bed, e limination of spicy foods,
and exercise and diet strategies for weight loss. If these interventions do not work, initial medical
therapy is usually aimed at ac id suppression, and includes proton pump inhibitors (PPIs) and H2
antagoni sts. If e ither of these therapies alleviates symptoms, the diagnosis of GERD may be
assumed. A trial for the emp iric use of proton pump inhi bitors (PPls) demonstrated a sensitivity
of up to 84% for the diagnosis ofGERD (16, 17). In tria ls investigating the use ofa proton pump
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inhibitor in patients with non-cardiac chest pain, a 7-day trial with omeprazole had a sensi ti v ity

of 78% and speci fi c ity of 86% for the diagnosis of GERD (J 8). Generally, af'teran
empiric trial with acid suppression, further invasive investigations are o nly be done for patients
with an unclear diagnosis secondary to mixed reflux and gastrod uodenal symptoms or atypical
symptoms, persistence of symptoms with a trial of medication, symptoms suggestive of severe
esophagitis such as hematemesis or persistent dysphagia, or when other diagnoses (such as
esophageal malignancy or infective or drug-induced esophagitis) are entertained.
Endoscopy may be utilized in the diagnosis ofGERD, though again, wi th the advent of
PPI trials, endoscopy is usually used only to demonstrate the presence of Barrett's esophagus.
Endoscopic find ings correspond to the severity of the disease, with initial findings including
edema, erythema, and friability, and later findings consisting of erosions and finally, ulcers.
Howevei~

while the sensitivity is 90-95%, the spec ificity is on ly 60% ( 19). Esophageal biopsy

may be done in conjunction with endoscopy to further identify Barrett's esophagus.
Esophageal pH measurement is the gold standard for the demonstration of pathologic
reflux . This method can demonstrate the relat ionship between reflux episodes and associated
symptoms. T hough invasive tests (such as pH measurement or endoscopy) exist, the diagnosis of
GERD is primarily made on a clinical basis,

TREATMENT

The treatment ofGERD consists of several strategies. The initial treatment is usual ly
lifestyle alteration. This includes head of bed e levation, smoking cessation, dietary changes
(i ncluding the e limination or restrict ion of fatty or spicy foods), restriction of a lcohol, weight
loss, and the restriction of meals immed iately before bedtime. Initi ally, patients may try antacids
or over the cou nter H2-receptor antagonists. H2 receptor antagonists have been shown to
significantly decrease heartburn (20). Initial prescribed therapy is usua lly a tria l of proton pump
inhibitors. PPIs have been found to be superio r to H2-antagonists in the treatment of GERD, with
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better relief of symptoms and a return to Donnal esophageal histology (20). Should patients
remain refractory to PPIs, a switch to a different brand ofPPI or an addition of a second dose may
be warranted. Maintenance therapy usually consists of a long-term regimen ofPPIs.

PREVALENCE
In 1976, the incidence of symptomatic gastroesophageal reflux was evaluated through the
distribution of a questionnaire that revealed that 7% of the subj ects experienced heartburn daily.
14% noted heartburn weekly. and 15% experienced it once a month, giving a total of36% of
subj ects baving heartburn at least monthly. This study also noted that age, sex, and hospitalization
did not signifi cantly affect incidence, and that the most common precipitating factors included
fri ed foods, "spicy" foods, and alcohol (21).
Currently, the prevalence ofGERD varies, depending on the method of diagnosis.
However, despite w hich method is used, the prevalence does appear fairly common. Locke et a l
conducted a validated self-report questionnaire with 2200 subjects in Olmstead County,
Minnesota, that demonstrated a prevalence of 19.8% of week ly heartburn and/or regurgitation
(22). In a population in Finland, Isolauri et al found a prevalence ofGERD (defined as daily
heartburn and/or regurgitation) of 10.3%, noting th at sign ificant risk factors included age, obes ity,
pregnancy, and cigarette smoking (23). Interestingly, the prevalence of GERD appears to be
lower in Asian and African nations. For example, in 1999, a cross-sectiona l survey of subjects in
Singapore demo nstrated a mean prevalence of reflux-type symptoms (heartburn and/or acid
regurgitation) of5.5%, with a prevalence of7.5% in Indian subjects, 0.8% in Chinese subjects,
and 3.0% in Malay subjects (24). The reasons behind this glo ba l difference are unclear, though
the authors postulated that there may be unknown geneti c factors.
Most of this type of research has been done on the prevalence of GERD in the adult and
pediatric populations, while less research has been done on its presence in the young adult
population. The research that has been done suggests that GERD is common in this population as
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well. Somi et al performed a cross·sectional study on a young population in Tabriz, Iran, with a
mean age of22.48. In this population, the prevalence of heart bum andlor acid regurgitation
experienced weekly was 6.3% and experienced monthly was 13%. The symptoms were most
often rated as mild to moderate. The authors noted that there was no significant gender or age
difference; however, risk factors included a higher BMI and the use of coffee and tea. Also noted
was the fact that GERO symptoms were reported less in subjects w ith no family history of upper
gastrointestinal disease, as well as in students in "higher rank fields" (25).
The prevalence of GERD appears to be increasing over time. El-Serag et a l reported a
signific!,!nt increase in hospitalization rates for GERD from 1970 to 1995 (26). The authors of the
paper described above that investigated the prevalence of reflux-type symptoms in Singapore reinterviewed the same subjects 5 years later. The prevalence had increased to 10.5% -- 11.7% in
Indian subjects, 9.4% in Chinese subjects, and 11.6% in Malay subjects (27). A systematic
statistical analysis of population-based stud ies investigating the prevalence of at least weekly
heartburn and/or regurgitation, studies investigating the prevalence ofGERD in the same
population at separate times, and studies investigating the prevalence ofGERD symptoms and
esophagitis in primary and secondary care demonstrated a significant upward trend in the
prevalence of reflux symptoms (28).

THE GROWING PRESENCE OF ADVERTISEMENTS
Marketing for medications has changed greatly in the past thirty years, with a significant
increase in direct to consumer advertising. An increasing amount of research is being performed
to investigate the effects of this advertising on consumer perceptions. Much of this research has
focused on the FDA Modernization Act of 1997, which dictated no limit on money spent for the
advertisement of a medical condition and a treatment. It has been proposed that this act led to a
significant increase in the amount of money put into advertisements by pharmaceutical
companies. However, whether this act was directly responsible for this increase remains
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controversial, with some research pointing to the fact that spending in this sector began to
increase before 1997, when the act was passed (29). Whether or not the act was the most
significant factor in the increase in the amount of money spent in this sector, it is clear that
funding for marketing has increased in recent years. In 2000, phannaceuticaI companies spent
approximately $2.5 billion on direct to consumer marketing, nearly triple the amount spent in
1996 and a disproportionately higher amount than that spent on other forms of marketing (29).
Different advertising methods are used in marketing toward the consumer. A content
analysis of advertisements for prescription drugs from 1989 to 1998 by Bell et al demonstrated a
dramatic increase in the number of new advertisements and brand introductions, with the most
common appeals being effectiveness, symptom control, innovativeness, and convenience.
Interestingly, they found while most ads were gender-neutral, those that were not tended to be
directed toward women (30). Whether this marketing presents a clear and unbiased picture to the
consumer has been the subject of much debate. Research done by Kaphingst et al has shown
limitations of television advertisements that may lead to possible misinterpretation by the
consumer. These include a greater amount of time spent on benefits rather than risks, the use of
both medical and lay terms that may pose a problem to the consumer with limited literacy ski lls,
the presentation of possible risks in one continuous fashion especially when accompanied by only
positive or neutral (rather than negative) images, and an emphasis on the advertised medication
rather than on the medica l cond ition the medication was meant to treat (31). A study by Huh et al
that examined direct to consumer websites showed that while a balanced amount of information
regarding both risks and benefits was presented, the modes of presentation differed. For example,
infonnation regarding benefits of a medication was more easily accessible than information
regarding ri sks. This may affect the consumer's perception of that medication (32).

Despite the controversy regarding whether direct-to-consumer marketing fairly
and accurately provides information, it is clear that advertisements for medications affect
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consumers. Exactly how the increased amount of marketing aimed at the consumer
affects consumer perception of disease and medications has been investigated in several
studies. 10 a random-digit dialing telephone survey with a random household member
selection procedure, subjects exhibited a mean awareness of advertisements of3 .7 out of
10 drugs. This awareness was associated with prescription drug use, media exposure,
positive attitudes toward direct-la-consumer marketing, poorer heaJth, and insurance
status. Subjects were noted to hold several misconceptions about the advertising of
medications, including the idea that only "completely safe" drugs could be marketed.
Finally, the authors noted that advertisements led to 33% of the subject population to ask
physicians for infonnation regarding a drug, and 20% of the subject population to ask for
a specific prescription (33). The same research group looked at patients' reactions to a
scenario where their physician refused an advertisement-motivated drug request.
Interestingly, the most likely reaction was disappointment. A lower percentage of the
patients surveyed were likely to try to persuade the physician to prescribe the medication,
or change physicians in order to find one who would prescribe the drug. From these
responses, the authors concluded that since a large percentage of patients would react
negatively to a physician'S refusal to consent to an advertisement-motivated drug request,

ft was clear that physicians need to be aware of patients' attitudes toward advertisinginduced drug requests (34). Further research by Mintzes et al demonstrated that a greater
percentage of patients with a higher rate of exposure to OTC marketing requested
advertised medications than did patients with a lower rate of exposure. Furthermore,
patients that requested medications marketed in this fashion were more likely to receive
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one or more new prescriptions for the requested medication or an acceptable alternative,

than were patients who did not request these medications (35).
While much research has been conducted on the effect of direct to consumer
marketing in general, few investigations specifically aimed towards GERD have been

completed. One study looked at how DTC marketing influences patients' shift from one
PPI to another. The investigators completed a retrospective cohort study of health claims

data from a large database that monitored claims for health benefit programs oflarge
employers. The claims for lansoprazole and omeprazoie were investigated. DTC
marketing was investigated by assigning an advertising level by geographic location,

such that areas were divided into high and low expenditure categories. The authors of the
study noted that omeprazole. but not lansoprazoie, was advertised during the year in
which the study took place. While switching from one PPJ to another was common for
the naIve PPJ user, switching specifically from lansoprazole to omeprazole (61.9%) was
more common than switching from omeprazole to lansoprazole (38.1 %). The authors
postulated that this difference may have been related to the increased level of marketing
for omeprazole. Logistic regression modeling demonstrated that a high level of direct to
consumer marketing was associated with a switch to the advertised product. In addition,
the presence of advertising for omeprazole was a significant predictor for switching to
omeprazole. The authors did note several limitations to the study. First, the current PPI
market is more complicated than the market at the time of the study (1998), and the
existence of more sophisticated advertising campaigns, and tiered cost-sharing and
therapeutic switching programs under specific health insurance plans, may make the data
from the study inapplicable to today's.patient population. Second, the study excluded
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patients eligible for Medicaid

or over the age of 65 years, who may have different

patterns afuse that could have affected the analysis. Third, the investigators were unable
to control for other variables that could have affected patient product use, such as
pharmaceutical sampling, patient education level, and patient income. Finally, the use of
the database did not alJow for the analysis of the degree of appropriate PPI switching. For
example, part of the motivation to switch from one PPI to another could have been the
persistence of worrisome symptoms that were not being effectively controlled by the
initial PPJ. Despite these limitations, this study demonstrated a possible relation between
direct to

consu~er

marketing and switching from one PPI to another (36). Fendrick et al

conducted a 3-month observational study that detennined that consumers accurately selfselected to use omeprazole for frequent heartburn, complied with the product label that
called for a 14-day regimen, and sought physician help for use of more than14 days of the
medication (37). This may indicate that consumers respond accurately to advertisements
for GERD medications.

HYPOTHESIS/AIMS
Our hypothesis is that a relationship may exist between the se lf-perception of reflux
symptoms and the increasing prevalence of advertisements for medications. Our aim was to
determine the prevalence ofGERD symptoms and the level of DTC advertisement exposure in a
young adult population. We sought to determine if advertisement exposure to PPls influenced the
perception ofGERD symptoms.
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METHODS
A questionnaire regarding the level and severity of GERD symptoms and the exposure
and influence ofDTC advertisements was presented to Yale Univers ity students. This study was
approved by the Human Investigations Committee at the Ya le University School of Medicine.

STUDY POPULATION
Subjects were recruited from undergraduate and graduate classes at Yale University. The
Inclusion criteria consisted of undergraduate or graduate students at Yale Univers ity and
completi on of the questionnaire, while exclusion criteria consisted of non-English speaking
subjects and subj ects under the age of 18 or over the age 0[30.

STUDY DESIGN
A questionnaire was designed to assess the self-perception of GERD symptoms, as we ll
as possible effects ofDTC advertisements on patients' self-perceptio n of disease, First, the scale
for the self-perception of GERD sym ptoms (question I) was utilized from a recent study that
va lidates a simple diagnostic questionnaire for gastroesophageal reflux d isease symptoms, w ith
the permiss io n of the authors of that study (38), These symptoms were stratified into two
categories: the heartburn symptoms were defi ned as " a burning fee ling behind your breastbone"
and "pain behind your breastbone," whi le the regurgitation symptoms were de fined as "an acid
taste in your mouth" and " unpleasant movement of materia l upwards from your stomach", The
subj ects were asked to detail the frequency of these symptoms over the past 4 weeks, using the
fo llowing sca le: "d id not have", " less than o ne day a week", "one day a week", ''2·3 days a
week", "4-6 days a week", "daily", The subjects were then asked to detai l the severity of these
symptoms over the past 4 weeks, us ing the fo llowing scale: "did not have", "very mild", " mild",
" moderate"> "moderately severe", or "severe" , In addition to these survey questions, 15 questions
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(questions 2~ 16) that were designed to identify a possible effect of advertisements for medications
on the self-perception of reflux were developed. These questions included three questions
designed to look at the subjects' familiarity with advertisements for any medications, and three
questions designed to look at the subjects' familiarity with advertisements specifically for reflux.
Five questions were asked about the use of reflux medications, physician visits for reflux

.

symptoms, and whether the subjects believed they were influenced by advertisements for reflux
medications. Demographic questions included the subjects' age, sex, alcohol and tobacco history,
and use of prescription and over-the-counter medications. All responses were anonymous. The
questionnaire was tested on a focus group (n= 19), whose suggestions were incorporated into the
final questionnaire. (Please see end of document for the GERD Questionnaire.)
Initially, the course coordinator for the departments of English, Anthropology, History,
Engineering and Applied Sciences, American Stud ies, and African-American Studies at Yale
Un iversity and the School of Public Health at Yale University were contacted in order to obtain a
subject group that was representative oftoday's young adult popu lation, based on sex and race.
After obtaining approval from the department heads, professors were contacted to ensure that the
distribution of questionnaire to their classes would be allowed. At the end of class, the purpose of
the study was explained, and the questionnaire and an infonnation sheet for participation in a
research project were distributed to each student in that particular class. Completed
questionnaires were collected that day. The results of each completed questionnaire were
compi led in a database.
(The development of the questionnaire was perfonncd by Shei la Kumar, Harry Aslanian
M.D., and Priya Jamidar M.D. Distribution of the questionnaire and the compilation of the data
was completed by the primary researcher, Sheila Kumar. Statistical analysis was performed by
Shei la Kumar in conjunction with Dr. Valentine Njike at the Yale Prevention Research Center.)
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RESULTS
DEMOGRAPmC INFORMATION
169 subjects were studied, compris ing 116 female s and 53 males, with a mean age of
22.26 years.
28.6% of the subject group reported the use of prescription medication s, most commonly
birth control. 66.67% of this population reported using 1 medication, 31.25% reported 2
medications, and 2.1 % reported 3 medications. Meanwhile, 18.5% of the total subject group
reported the use over the counter medications, most commonly analgesics. 71% of thi s population
reported using I medication, 25.8% use 2 medications, and 3.2% use 3 med ications.
2.38% of the subject population smoke tobacco (75% of this population smoked less than
1 pack

~r

day, while 25% smoked greater than 1 pack per day). 75% of the subject population

drink alcohol (13.49% drink 2-3 times a year, 48.4'1% drink 2-3 times a month, 37.3% drink 2-3
times a week, and 0.79% drink daily).

GERDSYMPTOMS
The first symptom we investigated was "a burning feeling behind the breastbone!' 23.8%
of the subject group reported this sensation, with the majority experiencing it < 1 day a week
(5 75%) and rating it "very mild" (40%), The second symptom we investigated was " pain behind
the breastbone:' 17,9% of the subject group reported this sensation, w ith the majority
experiencing it < 1 day a week (70%) and rating it "very mild" (46,67%). The third symptom we
investigated was "an acid taste in the mouth." 27.4% of the subject group reported this sensation,
with the majority experiencing it < I day a week (60.9%) and rating it "very mild" (54.3%). The
fourth symptom we investigated was "unpleasant movement of material upwards from the
stomach:' 36,9% of the subject group reported this sensati on, with the majority experiencing it
< I day a week (62,9%) and rating it "very mild" (41.9%).

15
For eacb category of symptoms (heartburn and regurgitation), we added up the scores for
severity (0 = " did not have," t = " less than one day a week," 2

=

"one day a week," 3 = "2-3 days

a week," 4 = "4-6 days a week," and 5 = "daily") and frequency (0 = "did not have," 1 = "very
mild," 2 = "mild," 3 = "moderate," 4 = " moderately severe," and 5 = "severe") for a final score.
The minimum possible score was 0, while the maximum possible score was 20. We used two
cutoff scores. First, a score of 8 corresponds to mild symptoms one day a week. This would be a
c linically significant score, and would usually warrant intervention by a physician. We also used
a score of 6, which corresponds to less stringent diagnostic criteria of e ither mild symptoms less
than one day a week or very mild symptoms one day a week. This is also a cl inically relevant
score. We believe that using these scores as a way to determine the subjects in our population
who suffer from heartburn, regurgitation, or both heartburn and regurgitation, is valid because the
diagnosiS of gastroesophagea l reflux di sease is a clinical diagnosis that is usually based on the
patient's self-reporting of sympto ms .
Using a score of 8 as the cutoff, 3.57% (6) of the su bj ect population reported heartburn
symptoms, 8.92% (15) reported regurgitation symptoms, and 1.79% (3) reported both heartburn
and regurgitation symptoms. Using a score of6 as a cutoff, 20.24% (34) of the subject population
reported heartburn symptoms, 27.38% (46) reported regurgitation symptoms, and 9.52% (16)
reported both heartburn and regurgitation symptoms.
Please see Figure I.
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Figure I

Frequency and Severity ofGERD Symptoms
Freauency

Severity

" Burning feeling behind
the breastbone" "" 40
(23.8%)

< I day aweek = 23 (57.5%)

Very mild "" 16 (40%)
Mild = 12 (30%)
Moderate = 10 (25%)
Moderately severe = 1 (2.5%)
Severe = I (2.5%)

" Pain behind the
breastbone" = 30 (1 7.9%)

< I dayaweek = 2 1 (70%)

I day a week = 10 (25%)
2-3 days a week = 5 (12.5%)
4·6 days a week = 2 (5%)
Daily = 0

I day a week = 6 (20%)
2-3 days a week = 2 (6.67%)
4-6 days a week = I (3.33%)
Daily = 0

Very mi ld = 14 (46.67%)
Mild = 12 (40%)
Moderate = 3 (10%)
Moderately severe =: 0
Severe = I (3.33%)

"An acid taste in the
mouth" = 46 (27.4%)

< I day a week = 2 8 (60.9%)
I day a week = 12 (26.1%)
2-3 days a week = 5 (10.9%)
4-6 days a week = I (2.2%)
Daily = 0

Very mild = 25 (54.3%)
Mild = )4 (30.4%)
Moderate = 4 (8.7%)
Moderately severe = 2 (4.3%)
Severe = I (2 .2%)

"Unp leasant movement of
materia l up wards from the
stomach" = 62 (36.9%)

< I day a week = 39 (62.9%)

Very mild = 26 (41.9%)
Mild = 22 (35.5%)
Moderate = 11 (17.7%)
Moderately severe = 2 (3.2%)
Severe - I (1 .6%)

I day a week = 13 (2 1.0%)
2-3 days a week =- 7 (11.3%)
4-6 days a week =- 3 (4.8%)
Daily = 0

EXPOSURE TO ADVERTISEMENTS FOR MEDICATIONS
In th e subj ect population, 92.3% (1 55) reported having been exposed to ads for
m edicatio n s, with the most common mode of exposure through magazines/n ewspapers, the
internet, and television (30.3%). P lease see Fi g ure 2.

Figure 2- Frequency of Modes of Exposure to Advertisements fOr Medications
MODE OF EXPOSURE

NUMBER OF SUBJECTS

Magazin 7s/newspapers + internet + television

47 (30.3%)

Magazines/newspapers + television

3S (22.6%)

Television

28 (18.1%)

Mal1.!lzinesfnewsoaoers + internel + television + radio

20112.9%)
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Of the subjects who reported exposure to ads for medications, 67.3% reported being able
to recall the conditions that those med ications treated . The most common of these medications
were heartburn/reflux (55.8%). Please see Figure 3.

Figure 3- Frequency of Medical Conditions Recalled Through Advertisements

RECALLED CONDITIONS

NUMBER OF SUBJECTS

Heartbumlreflux

63 (55.8%)

Depression

,

47 (41.6%)

Sexual disorders

46 (40.7%)

Finally. of the subjects who reported exposure to ads for medications, 54 .2% reported
being able to recall the names of these medications. The most common class of names recalled
was for sexual disorders (45.1 %), includ ing Cialis and Viagra. Please see Figure 4.

Figure 4- Frequency o(Medicalions Recalled Through Advertisements

NAMES OF MEDICATIONS RECALLED

NUMBER OF SUBJECTS

Sexua l disorder medication
(Cia lis, Viagra)

41 (45. 1%)

Heartbumlreflux medication
(Prilosec, Pepcid, Turns)

36 (39.6%)

Depression medication
(Cymbalta)

27 (29.7%)
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EXPOSURE TO ADVERTISEMENTS FOR HEARTBURNIREFLUX MEDICATIONS
We also asked about exposure to advertisements for GERD specifically. In the subject
population, 89.29% reported exposure to advertisements for heartburn/reflux, with television as
the most common mode of exposure (56%). Please see Figure 5.

Figure 5- Frequency of Modes of Exposure to Advertisements [or GERD Medications

MODE OF EXPOSURE

NUMBER OF SUBJECTS

Television

84 (56%)
26 (17.3%)

Magazines/newspapers + television

Maga~inesJnewspapers

+ internet + television

18 (12%)

Of the population that reported having been exposed to ads for heartbumlrenux
medications, 38.7% reported being able to recall names of these meds, with Nexium as the most

commonly recalled medication (27.7%). Of the population that reported having been exposed to
ads for heartburn/reflux medications, 36.3% reported being able to recall details of these
advertisements. The most common ly recalled detail, recorded by 32.3% of this population, was
the slogan "The purple pill." Please see Figure 6.
Figure 6- Frequency of Recalled Names ofGERD Medications
NAMES OF MEDICATIONS RECALLED

NUMBER OF SUBJECTS

Nexium

18 (27.7%)

Turns

17 (26.2%)

Prilosec

15 (23. 1%)

Pepcid

13 (20%)

Prcvacid

10 (15.4%)
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GERD SYMPTOMS AND EXPOSURE TO HEARTBURNIREFLUX ADS

First, we investigated the relationship between exposure to advertisements for
heartburn/reflex meds and self-reported GERO symptoms. According to responses on questions

7 (familiarity with advertisements for heartburn/reflux medications), 8 (abi lity to recall names of
heartburn/reflux medications), and 9 (ability to recall detai ls of advertisements for
heartburn/reflux medications), we stratified three levels of exposure to heartburn/reflex
advertisements into the following categories: "Low" = answered yes to question 7, "Moderate" =
answered yes to question 7 and 8, "High" = answered yes to 7,8, and 9. For GERD symptoms,
we scored the severity and frequency questions for the two parts of question 1 ( Heartburn and

Regurgitation symptoms) as detailed above. When we used 8 as a cutoff score, we defined
"Heartburn" as a score greater than or equal to 8 and "No Heartburn" as a score less than 8,
"Regurgftation" as a score greater than or equal to 8 and "No Regurgitation" as a score less than
8, and " Heartburn and Regurgitation" as a score of greater than or equal to 8 in both the
"Heartburn" and "Regurgitation" categories and "No Heartburn and Regurgitation" as a score of
less than 8 in both the "Heartburn" and "Regurgitation" categories. We defined these terms
similarly when using 6 as the cutoff score. Again, a score of 8 wou ld generally warrant treatment
by a physician, wh il e a score of 6 is also clinically relevant.
First, we exam ined the relationship between levels of exposure to advertisements for
~eartburnlreflux

medications and the self-reporting of heartburn symptoms. Using both cutoff

scores, subjects exposed to the low, moderate, and high leve ls of exposure to advert isements for
heartburnlreflux medications were not more likely to report heartburn symptoms than subjects not
exposed to these advertisements.
Please see Figures 7 and 8.
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Figure 7- Relationship Between Exposure (0 Advertisements for GERD Medicat ions and Self-Reported
H eartburn Symptoms (Using a Score 0(8)

Low Level of

Exposure to

.

Heartburn

No Heartburn

p-Value

Yes = 6 (3 .57)
No ~ 0 (0.00)

Yes = 144 (85.71)
No = 18 (10.71)

1.0000

Yes = 2 (2.4 1)
No ~ 0 (0.00)

Yes = 63 (75 .90)
No ~ 18 (21.69)

1.0000

Yes = I (J .82)
No ~ 0 (0.00)

Yes = 36 (65.45)
No = 18 (32.73)

1.0000

Heartbum/Re flux

Ad,

Moderate Leve l of

Exposure to
HeartburnlRe flux
Ads '

High Level of
Exposure to
HeartbumlReflux
Ads'

Number of S ubJects (percentage)

Figure 8- Relationship Between Exposure to Advertisements (or GERD Medications and SelfReported
Heartburn Symptoms (Using a Score 0(6)

Heartburn

No H eartburn

p-Value

Low Level of
Exposure to
H eartbumIReflux
Ad,

Yes = 13 (7.74)

Yes = 137(8 1. 55)

0.6652

Moderate Level of
Exposure to
HeartbumlRetlux
Ads ·

Yes = 7 (8.43)
No ~ 2 (2 .41)

Yes = 58 (69.88)
No = 16 ( 19.28)

1.0000

High Level of
Yes = 5 (9.09)
No = 2 (3.64)
Exposure to
H eartburn/Reflu x
Ads·
Number of SubJects (percentage)

Yes = 32 (58.1 8)
No = 16 (29.09)

1.0000

.

No ~2 (1. 1 9)

No

~

16 (9.52)
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We then examined the relationship between levels of exposure to advertisements for
heartburn/reflux medications and the self-reporting of regurgitation symptoms. Using both cutoff
scores, subjects exposed to the low, mode rate, and high leve ls of exposure to advertisements for
heartburn/reflux medications were not more likely to report regurgitation symptoms than subjects
not exposed to these advertisements. Please see Figures 9 and 10.

Figure 9- Relationship Between Exposure to Advertisements for GERD Medications and Sel[.Reported
Regurgitation Symptoms (Using a Score orB)

Heartburn

No Heartburn

p-Value

Low "'Levelof
Exposure to
Heartburn/Reflux
Ads'

Yes =: 15 (8.93)
No = 0 (0.00)

Yes = 135 (80.36)
_No = 18 (10.71)

0.3743

Moderate Level of
Exposure to
HeartbumfReflux
Ads'

Yes = 8 (9.64)
No = 0 (0.00)

Yes ;O 57 (68.67)
No = 18 (21.69)

0.1910

High Level of
Exposure to
HeartburnlReflux
Ads'

Yes = 4 (7.27)
No = 0 (0.00)

Yes ;o 33 (60.00)
No = J8(32.73)

0.2911

.

Number of Subjects (percentage)
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Figure 10- Relationship Between Exposure toAdvertisemenls (or GERD Medications and Self.Reported
Regurgitation Symptoms fUsing a Score 0(6)

Heartburn

No Heartburn

v·Value

Low Level of

Yes = 13 (7.74)

No - 2 (1.19)

Yes = 137 (81.55)
No = 16 (9.52)

0.6652

Exposure to
HeartbumIReflux
Ads '

Moderate Level of

Yes = 7 (8.43)
No = 2 (2.4 1)

Yes = 58 (69.88)

1.0000

Yes = 5 (9.09)
High Level of
Exposure to
No - 2 (3.64)
HeartburnlReflux
Ads '
Number of SubJects (percentage)

Yes = 32(58. 18)

Exposure to

No = 16 (19.28)

Heartburn/Reflux
Ads '

1.0000

No = 16 (29.09)

We also looked at the relationsh ip between leve ls of exposure to advertisements for
heartburn/reflux med ications and the self-reporting of heartburn and regurgitation symptoms.
Using both cutoff scores, subjects exposed to the low and moderate levels of exposure to
advertisements for heartburn/reflux medications were not more likely to report heartburn and
regurgitation symptoms than subjects not exposed to these advertisements. Please see Figures II
and 12.
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Figure J /- Relationship Between Exposure (a Advertisements (or GERD Medications and SelfReported
fleartburn and Regurgitation Symptoms (Using a Score 0( 8)
Heartburn AND
Regurgitation

No Heartburn AND
Regurgitation

p-Value

Yes = 3(1.79)
No = 0 (0.00)

Yes = 147 (87.50)
No= 18 (10.71)

1.0000

Moderate Level of
Exposure to
Heartburn/Reflux
A ds'

Yes = 1 ( 1.20)
No = 0 (0.00)

Yes = 64 (77.1 J)
No = J8 (2 1.69)

High Level of
Exposure to
HeartbumIReflux

Yes = 0 (0.00)
No = 0 (0.00)

Yes = 37 (67.27)
No = 18 (32.73)

Low Level of
Exposure to

HeartburnlReflux
Ads·

1.0000

Unable to be computed.

Ads'
Number of SubJects (percentage)

Figure 12- Relationship Between Exposure (0 Advertisements (or GERD Medica/ions and Se/FReporled
Hear/burn and Regurgitation Symptoms (Using a Score 0(6)

Heartburn AND
Regurgitation

No Heartburn AND
Regurgitation

p-Value

Low Level of
Exposure to
HeartbumfReflux
Ads '

Yes = 6 (3 .57)
No ~ I (0.60)

Yes = 144 (85.71)
No = 17 (10.12)

0.5546

Moderate Level of
Exposure to
Heartburn/Reflux
Ads·

Yes = 4 (4.82)
No = I (1.20)

Yes = 61 (73.49)
No = 17 (20.48)

High Level of
Yes = 2 (3.64)
No = I (1.82)
Exposure to
Heartburn/Reflux
Ads ·
Number of Subjects (percentage)

Yes = 35 (63.64)
No = 17(30.91)

1.0000

1.0000

24
Finally, we looked at the relationship between the responses to quest'ion 14, where we asked
directly " Have advertisements for medications influenced your approach to heartburn or acid
reflux symptoms?" and exposure to advertisements for medications for heartbumfreflux. We
stratified the responses to question 14 into: Influence by Ads = responded yes to any part of thi s
question and No Influence by Ads

=

responded no to th is question. Subjects exposed to the low,

moderate, and hi gh levels o f exposure to advertisements for heartburn/reflux medications were
not morc likely to report having been influenced by these ads. Please see Figure 13.

Figure J3- Relationship Between Self-Reporting oflnfluen ce by Advertisement and Exposure to
Advertisements

Influence by Ads

No Influence by Ads

p-Value

Low Level of
Exposure to
HeartbumlReflux
Ads'

Yes = 115 (68.45)
No = II (6 .55)

Yes = 35 (20.83)
No = 7 (4.17)

0. 1584

Moderate Level of
Exposure to
HeartbumlReflux
Ads"

Yes = 54 (65.06)
No = I I (13.25)

Yes = 11 (13.25)
No = 7 (8.43)

0.0577

High Level of
Yes = 30 (54.55)
Exposure to
No ~ 11 (20.00)
Heartburn/Reflux
Ads'
Number of Subjects (percentage)

Yes = 7 (1 2.73)
No = 7 (1 2.73)

0.1855

-

GERD SYMPTOMS AND PHYSICIAN V1SITSIUSE OF GERD MEDICATIONS
We also investigated the relationship between self-reported GERD sympto ms and the use
of physician visits and med ications for GERD symptoms. As above, we stratified question I into
Heartburn questions and Regurgitation ql:lestions, using both 8 and 6 as cutoff scores for
Heartburn, Regurgitation, and Heartburn AND Regurgitation.
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When using a cutoff score of 8, subjects who had seen a physician were more likely to
report GERD symptoms and subjects who had received a prescription for GERD medications
were marginally more likely to report heartburn symptoms. When using a cutoff score of 6,
subjects who had taken a medication for GERD and who had seen a phys ician were both more
likely to report heartburn symptoms. Please see Figures 14 and 15.

Figure /4- Relationship Between Use ofGERD Medications/ physician Visits! Prescriptions fOr GERD
Medications and Self-Reported Heartburn Symptoms (Using a Score 0(8)
Heartburn

No Heartburn

p-VaJue

Yes " 3 (1.79)
No " 3 (1.79)

Yes = 27 (16.07)
No" 135 (80 .36)

0.0708

forGERD "

Seen a Physician for
GERO'

Yes = 3 (1.79)
No " 3(1.79)

Yes = II (6.55)
No " 151 (89 .88)

0.0080

Received a
Prescription for
GERD Medication

Yes = 2 (1 . 19)
No " 4 (2.38)

Yes = 9 (5.36)
No" 153 (91.07)

0.0508

Taken Medications

.

Number of SubJects (percentage)

Fjgure J5- Relatjonship Between Use oLGERD Medications! Physjcian Visits! Prescriptjons (or GERD
Medications and Sel(Reported Heartburn Symptoms (Using a Score 0(6)

Taken Medications
forGERD •

Seen a Physician for
GERO '

Received a
Prescr iption for
GERD Medication'

Heartburn

No Heartburn

p-Value

Yes=7(4.17)
No" 8 (4.76)

Yes=23( 13.69)
No ~ 130 (77.38)

0.0067

Yes = 5 (2.98)
10(5.95)

Yes = 9 (5.36)
No = 144 (85 .7 1)

0.0035

No ~

Yes = 3 ( 1.79)
No = 12(7. 14)

Yes = 8 (4.76)
No " 145 (86.31)

0.0617

Number of SubJects (percentage)

26
When using both cutoff scores of 8 and 6, subjects who had seen a physician for GERD
symptoms and who had received a prescription for GERD medications were more like ly to report
regurgitation symptoms. When using a cutoff score of8, subjects who had taken a medication for
GERD were more likely to report regurgitation symptoms. Please see Figures 16 and 17.

Figure

16~

Relationship Between Use ofGERD Medications/ Physician Visits! Prescriptions for GERD

Medications and Self-Reported Regurgitation Symptoms (Using a Score 0(8)
Regurgitation

No Regurgitation

p-Value

Taken Medications
for GERD ·

Yes = 6 (3.57)
No ~ 9 (5.36)

Yes = 24 ( 14.29)

0.0304

No ~ 129 (76.79)

Seen a Physician for

Yes '" 8 (4.76)

Yes= 6 (3.57)

GERD'

No~7(4. 1 7)

No ~ 147 (87.50)

Yes = 5 (2.98)
No = to (5 .95)

Yes = 6 (3.57)
No = 147 (87.50)

.

Received a
Prescription for
GERD Medication

-

1.143E-06

9.613E-04

Number of SubJects (percentage)

Figure /7- Relationship Between Use ofGERD Medicotions! Physician Visits! Prescriptions for GERD
Medications ond Self..Reported Regurgitation Symptoms (lJsing a Score o(6)
Regur.e.itation

No Re.e.ure.itation

p-Value

Taken Medications
for GERD •

Yes = 8 (4.76)
No= 18(10.7 1)

Yes=22 (13.to)
No= 120(7 1.43)

0.0906

Seen a Physician for

GERD -

Yes = 9(S.36)
No= 17{lO. 12)

No = 137 (81.55)

Received a
Prescription for
GERD Medication'

No ~ 20 ( 11 .90)

Yes = 6 (3.57)

Number of SubJ ects (percentage)

Yes ~5(2.9 8)

Yes = 5 (2 .98)
No"" 137(8 1. 55)

U89E-05

0.0021
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When using both cutoff scores of 8 and 6, subjects who had seen a physician for GERD
symptoms were more likely to report heartburn and regurgitation symptoms. When using a cutoff

score of 6, subjects who had taken a medication for GERD were more likely to report heartburn
and regurgitation symptoms. Please see Figures 18 and 19.

Figure 18- Relationship Between Use ofQERD Medica/ions! Physician Visits! Prescriptions for GERD
Medications and Sel(.Reporled Heartburn and Regurgitation Symptoms (using a Score 0(8)

Regurgitation
Heartburn AND
Regurgitation

No Regurgitation

No Heartburn AND

D-Value
p-Value

Regurgitation

Taken MedicatiQns

Yes ~ 2(1.19)

No ~ 1' (0.60)

YeF 28 (16.67)
No ~ 137 (81.55)

0.0826

forGERD •

Seen a Physician

Yes ~ 3 (1.79)
No ~ O{O.OO)

Yes ~ II (6.55)
No~ 154(91.67)

4.689E-04

forGERD •

Number of SubJects (percentage)

Figure J9- Relationship Between Use o(GERD Medications/ Physician Visits! Prescriptions fOr GERD
Medications and Self-Reported Heartburn and Regurgitation Symptoms (Using a Score 0(6)
Heartburn AND
Regurgitation

No Heartburn AND
Regurgitation

p-Value

Taken Medications
forGERD •

Yes = 5 (2.98)
No = 2(1.19)

Yes = 25 (14.88)

0.0022

No ~ 136 (80.95)

Seen a Physician for

YeF4 (2.38)
No~3 (1.79)

No ~ 151 (89.88)

GERO·

Received a
Prescription. for
GERD Medication

Yes -= 2 (1.19)

.

No ~

Number of Subjects (percentage)

5 (2.98)

Yes = 10 (5.95)

Yes = 9 (5.36)
No = 152 (90.48)

9.4I3E-04

0.0685
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Fina lly. we looked at the re lationship between the responses to question 14, where we asked
directly " Have advertisements for medications infiuenced your approach to heartburn o r acid
reflux symptoms?" and physician visits for GERD symptoms/use of medications. None of these
relationships were statistically significant. P lease see Figure 20.

Figure 20· Relationship Between Use o(GERD Medications! Physician Visits! Prescriptions [or GERD
Medications and Self-Reporting oUnfluence bv Ads
Influence by Ads

No Influence byAds

p-Value

Taken Medications
forGERD' .

YeF 26 (15.48)
No = 100 (59.52)

Yes = 4 (2.38)
No = 38 (22 .62)

0.1035

Seen a Physician fo r

Yes = '11(6.55)
No = 115 (68.45)

Yes = 3 (1.79)
No = 39 (23.21)

1.0000

Yes = 9 (5.36)
No = II ? (69.64)

Yes = 2 (1.19)
No = 40(23.8 J)

0.7328

GERD'

Received a
Prescription for
GERD Medication '

Number of SubJects (percentage)

USE OF PRESCRIPTION/OTC MEDS AND EXPOSURE TO HEARTBURNIREFLUX ADS
We investigated the relationship between taking prescription medication regularly
(question 2) and the level of exposure to advertisements for heartbumlreflux. The subject
population who reported having a low, moderate, or high level of exposure to heartbum/reflux
ads was not statistica lly more like ly to a lready be taking prescription medications. Please see
Figure 21.
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Figure 21· Relationship Between Levels o(Exposure to Advertisements for GERD Medications and the Use
of Prescription Drugs

Takes Prescription
Medication Regularly

Does Not Take Prescription
Medication Regularly

p-Value

Yes = 45 (26.8)
No = 105 (62 .5)

Yes ~ 13 (1.8»
No ~ 15 (8 .9)

0.2367

HeartbumIReflex Ads '

Moderate Level of Exposure
to Heartburn/Refle x Ads '

Yes = 20 (24.1)
No = 45 (54.2)

Yes = 3(3.6)
No = 15 (18.1)

0.3727

High Level of Expos~e to
HeartbumIReflex Ads '

Yes = 12 (21.82)
No ~ 3 (5.45)

Yes = 25 (45.45)
No ~ 15 (27.27)

0.3353

Low Level of Exposure to

Number of SubJects (percentage)

We also investigated the relationship between taking over the counter medi cation
regularly and the level of exposure to advertisements for heartburn/reflux. The subject population
who reported having a low, moderate, or high level of exposure to heartburn/reflux ads was not
statistically more likely to already be taki ng OTe med ications. Please see Figure 22.

Figure 22- Relationship Between Levels orExposure to Advertisements for GERD Medications and the Use
orOTe Drugs
Takes OTC Medication
Regularly

Does Not Take OTC
Medication Regularly

p-Value

Low Level ofE;t(posure 10
HeartbumlRefle;t( Ads ·

Yes = 29( 17.3)
No= 12 1 (72.0)

Yes = 2( 1.2)
No = 16 (9.5)

0.5316

Moderate Level of Exposure to
1·leartbumlReflex Ads·

Yes - 13(l5.7)
No = 52 (62.7)

Yes - 2(2A)
No >; 16 (19.3)

0.5047

High Level ofExposurc to
HeartburnlReflex Ads ·

Yes = 7 (12.73)
No = 2 (3.64)

Yes " 30 (54.55)
No'"' 16 (29.09)

0.7017

Number of Subjects (percentage)
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EXPOSURE TO HEARTBURNIREFLUX ADS VS. EXPOSURE TO MEDICA nON ADS
We investigated the relationship between exposure to ads for medications in general and
exposure to ads for specifically heartburn/reflux. In this case, we looked at the answers to

questions 4 (familiarity with ads for medications) and 7 (familiarity with ads for heartburn/reflux
meds). The subject population who reported being exposed to ads for medications in general was
statistically morc likely to be familiar with ads specifically for heartburn/reflux meels. Please see

Figure 23.
Figure 23- Relationship Between Familiarity with Ads [or Medications and Familiarity with Ads
Specifically (or GERD
Familiar with ads for
heartburn/reflux meds

Not familiar with ads for
heartburn/reflux meds

p-Value

Yes = 141 (83.9)
No =· 9 (5.4)

YeS'" 14 (8.3)
No'"" 4 (2.4)

0.0360

.

Familiar with ads for
medications

-

Number of SubJecls (percentage)

EXPOSURE TO HEARBURNIREFLUX ADS + USE OF GERD MEDICATIONS
Finally, we looked at the relationship between subjects who reported a high level of
exposure and have taken medications for GERD symptoms. In the population of subjects who
reported a high level of exposure to heartburn/reflux ads and have taken a medication for GERD
symptoms, there was no statistical significance between the mean scores of subjects who reported
h~artbum

symptoms and those who did not, as well as between the mean scores of subjects who

reported regurgitation symptoms and those who did not.
Please see Figure 24.

Figure 24· Relation.ship Between High I.evel o{£.xposure to Heartburn/reflux Ads and Have Taken Medications {or
CERD

High Level of Exposure 10
Heartburnlrenux Ads and 1·lave Taken
Medications for GERD •
Mean (standard deVlallon)

Heartburn

-Value

Rc ur italion

P-Value

Yes '"' 2.67 (2.8)
No = 4.0 (2.8)

0.5559

Yes = 4.33 (4.4)
No = 4.0 (2.8)

0.9231

31

DISCUSSION

Prevalence of GERD
In this study. we determined the prevalence of GERD in the young adult population that

we examined to be between 1.79% and 8.92%, depending on the symptom used. Research has
determined a varying prevalence in an older population of values of anywhere between 5% and
45%, depending on the method of diagnosis, with these values increasing over time. However,
most of this research has been done on a subject group with a mean age in the 40's or 50's, and
very little research has been done on the prevalence ofGERD in a young ad ult population in the
Western hemisphere. It has been indicated that close to 50% of adults who experience end-stage
compl ications ofGERD (including Barrett esophagus) deny symptoms earlier in life. Thus, we
also wanted to determine whether the young adult population self-reports GERD symptoms, in
order to determine whether there is recall bias among the older asymptomatic population with
end-stage complications o r whether they are truly asymptomatic.
In this population, we found that the prevalence of GERD symptoms depended on the
characterizations used for diagnosis. 17.9% - 24.4% of the subject population reported heartburn
symptoms at any point during their li ves, while 27.4% - 36.9 % reported regurgitation symptoms
at any point. However, when making this diagnosis more stringent by including the actual scores
from the questionnaire, these values decreased. First, when using a cutoff score of 6 (which
corresponded to either mild symptoms less than one day a week or very mild symptoms one day a
week), 20.24% of the subject population reported heartburn symptoms, 27.38% reported
regurgitation symptoms, and 9.52% reported both heartburn and regurgitation symptoms. When
making the diagnosis more stringent by using a cutoff score of 8 (which represented mild
symptoms at least one day a week), 3.57% reported heartburn symptoms, 8.92% reported
regurgitation symptoms, and 1.79% reported both heartburn and regurgitation symptoms. Both of
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these cutoff scores are clinically relevant and would probably warrant treatment by a physician.
Since GERD is usua lly a clinical diagnosis with no further invas ive tests, we believe that these
prevalence values are valid .
The prevale nce values found in our study are lower than those found in many studies that
have determined the prevalence in adult populations. This difference may have several
explanatio ns. One possible contributing fac tor is obesity. A higher BMI is a risk factor for GERD,
and is a lso more common with increased age. Thus, it may be that the young population
examined in this study have a lower BMI than the older populatio ns examined in many of the
other studies, and therefore do not possess this risk facto r. The difference in preva lence may also
simply be due to.a lower self-perception of disease symptoms in a younger population versus an
older one, as it is often assumed that young people arc less attuned to physical symptoms of
di sease. In addition, an older population may be fo llowed by physic ians more regu larly, and thus
may have to examine any sympto ms more frequently. In contrast, the younger population
examined in this study may not be exposed to this level of health care as frequently. W ithout the
impetus by a medical care-giver to examine their physical well-be ing, the younger population
may be less likely to notice any symptoms of disease. Noted be fore was the statistic that a high
percentage of older adul ts who experience the end-stage complications of GERD deny symptoms
w hile younger. Perhaps some subjects in the young population have the pathophysiologic factors
th at lead to gastroesophageal re flu x, but for an unknown reason, do not experience the symptoms
of this re flu x. The population in this study is a we ll educated group in college. The study by Somi
et al that examined a young population in Iran indicated that the self-reporting of GERD
symptoms was lower in subjects " in high rank fie lds." F inally, there was a hi gher percentage of
fema les than ma les in our study group. Since males are more like ly than fema les to suffer from
GERO, perhaps the decreased percentage of ma les parti cipating in the study caused a decrease in
the overall preva lence of GERD found in the population that we used.
Inte restingly, the prevalence va lues found in thi s study are also lower than those found in
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the study by Sami et. Qualifications in comparing these two studies include the use of different
questionnaires. In addition, their study reported values for experiencing symptoms either weekly
or monthly, which are less stringent qualifications than those used in

OUf

study. Nonetheless, it is

interesting that the prevalence differs between the two studies. Several studies have determined
different prevalences in -different" populations. For example, the prevalence ofGERD has been
determined to be lower in Asian populations than in populations from the Western hemisphere,
with possible unknown genetic factors contributing to this difference. However, Middle Eastern
populations and populations in the Western hemisphere have not yet been compared. Unknown
genetic or cultural factors may playa role in this difference.

Relationship Between Direct to Consumer Marketing and the Self-Perception of GERD
Symptom"s
In our study, we also investigated the complicated relationship between exposure to
advertisements for medications and the self-perception of GERD symptoms. The growing
presence of direct-to-consumer advertisements has already noted to playa role in patients'
perception of disease. Research indicates that sometimes, such advertising may not present clear
and unbiased information to the consumer. Benefits to DTC marketing for GERD medications
include patient education. Jt is possible that a person who otherwise would not pay attention to
their GERD symptoms and thus would possibly progress toward complications of the di sease,
including esophageal adenocarcinoma, would now visit their physician in order to get treatment
for their heartburn/reflux. Thus, the benefit to DTC marketing includes the possible decrease in
future compli cations of GERD, including adenocarcinoma. The risks to DTC marketing include
the use of unnecessary medi cations. No medication is without side effects, and the use of a drug
cou ld lead to unnecessary complicati ons. The unwarranted use of GERD medicatio ns also
increase health care costs, through higher.costs for insurance plans that cover these medications.
We wanted to determine whether the young adult population is influenced by DTC marketing for
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GERD medications.

It is worth mentioning that the population used in this study did report a very high level
of exposure to advertisements for medications in general with 92.3% of the group noting that they
had been exposed, mostly through television, magazines! newspapers, and the internet. In fact,
54.2% were able to recall the specific names of these medications, mostly for drugs for sexual
disorders. On this background of a very high level of exposure to advertisements for medications,
a high percentage (89.29%) reported exposure to ads for heartburn/reflux medications, with those

subjects who reported a high level of exposure to advertisements in general more likely to report
a high level of exposure to advertisement specifically for heartburn/reflux medications. Of this
population, 36.3% reported being able to recall details of these advertisements. Interestingly, the
s logan "The purple pill" was the most commonly recalled detail, recorded by 32.3% of the
population that reported exposure to ads. It is often assumed that a young, healthy population
does not pay attention to those advertisements associated with disease or illness. However, with
36.3% of our study group reporting exposure to ads and 36.4% of that population able to reca ll
specific details, it is clear that direct-to-consumer marketing for heartburn/reflux medi cations is
being noticed by this young population. The specific slogan "The purple pill" is often labeled as
an effective advertisement -- it is clear that the young population examined in this study
remembers this catchphrase, and Nexium was, in fact, the most recalled medication . Thus, it
~ppears

that this catchphrase is effective advertising, because the public is able to remember the

medication it is promoting.
Despite the fact that this young adult population is aware of advertising for
heartburn/reflux medications, it does not appear that such advertising is linked to the selfperception of GERD symptoms. Using varying levels of stringepcy for the diagnosis of
s ignificant clinical symptoms (both mild symptoms one day a week and either mild symptoms
less than one day a week or very mild symptoms one day a week), there was no statistically
s ignificant relationship between exposure to advertising and GERO symptoms. Thus, while
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advertising appears to be effective in the products are highly reca lled, advertising does not appear
to affect the young adult population's self-perception of disease symptoms.
Although 12.5% of the subject group believed that advertisements for medications had
influenced their approach to heartburn/reflux symptoms (answered yes to question 14), there was
also no statistically sign ificant relationship between answering yes to this question and the selfperception of GERD symptoms. Thus, there appears to be a disconnect between the way this
population feels that advertising has affected them and their actual perception of disease
symptoms. Fina lly, it does not appear that a high level of exposure to heartburn/reflux ads
corresponds with the use of GERD medications or a higher perception of GERD symptoms.
However, interestingly, there do.es appear to be a relationship between the self-perception
of GERD symptoms and the actions of those who report such symptoms. Subjects who had seen a
physician' for GERD symptoms were more likely to report heartburn and regurgitation symptoms.

It may be that the subjects who report GERD symptoms are those people who are more sensitive
to any symptom, and thus would be more like ly to seek out care.
The lack of a relationship between exposure to DTC marketing and the self-perception of
GERD symptoms may have several causes. First, the population used in this study is highly
educated. Perhaps with education comes skepticism of advertisements, since education at these
high levels is often taught through continua lly questioning everything. Though these young
s~dents

may be exposed to the ads and retain the information promoted by the ads, they may be

more like ly to view such information with skepticism, such that they question the va lidity of the
ads. If this is true, they are less likely to be innuenced.

Limitations
Severa l limitations are present in this study. The first limitation concerns the
questionnaire itself. While several of the questions were borrowed from a previously validated
questionna ire, the other questions have not been va lidated. The additional questions may also
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affect the validity of the borrowed questions. In addition, using a survey questionnaire may lead
to subject bias. The subjects that completed the questionnaire may have been those subjects more
likely to have stronger opinions on the questions asked.
The second limitation concerns the patient population used in this study. First, the
characteristics of the population used may not allow for the application of the results from this
study to the entire young adult popu lation. The subjects in this study were young, highly-educated
adults, and as such, represent a discrete population. The e ffects of soc ioeconomic status and leve l
of education o n the self-perception of disease may mean that the results found for this population
may not be applicable for a different young adult popu lation. Another limitation concerns the
group size. The populations for several

~ fth e

specific sub-groups at w hich we looked were very

sma ll . Statistical analysis of populations this small may lead to a skewed view of the data.

Conclusion
Despite these limitations, this study demonstrates a low prevalence ofGERD symptoms
in a young adult population. In addition, it appears that there is no relationship between direct to
consumer marketing and exposure to advertisements for medications and self perception of
GERD symptoms in this population.
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GERD questionnaire
Age (yes) _ _

Gender (

M

IF)

1. Please answer each of the following 2 questions by ch ecking~ box per row.
Thinking about your symptoms over the last 4 weeks, how often did you have the following?
Did nOI have
a.

b.

A burning
feeling

DO

behind your
breastbone
Pai n behind

DO

. Less than one:,
: daya~eek "

02

your

breastbone
c. An acid
taste in your

d.

I?i' .:;' . ~~.. ",

04

'.

DO

01

02

OJ

04

Di

D2

OJ

04

mouth
Unpleasant
movement

of material
upwards
from the

DO

,

05

:'"

Ie· .

I' ,

slO1ll3ch

.

Thinking about your symptoms over the last 4 weeks, how would you rate the following?
Did not have

,.
b,

,.
d.

Moderate

Mild

Very Mila

Mode rately

,

~ Severe

Severe
ft. burning
fee ling behind
your
breastbone ".
Pain behind
your
breastbone .......
An acid taste
in you r mouth ..
Unpleasant
movement of
material
upwards from
the stomach ..

DO

01

D2

OJ

04

05

DO

01

02

OJ

04

05

DO

01 ,

04

.oS'

'D4

O S ",

,
.

,

..,
.

•

01 >

03

D2

2. Do you take any prescription medications regularly (
If yes, please list them:

•

. ",
.

DO

,

.~" D3 ·

D2

Yes

3. Do you take any over the counter medications regularly? (
If yes, pl ease list them :

I

Yes

."
-'".

No

)

I

No

)

4. Have you seen advertisements for prescription medications? ( Yes I No )
If yes, in which media fannals have you seen these advertisements? (Check all that apply.)
magazines, newspapers
television
internet
radio
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5. Do you recall what conditions they treat? (
Jfyes, please list them:

Yes

I

6. Do you recall the names of any of the medicatio ns? (
J[ yes, please list them: .

No

Yes

)

I

No

)

7. Have you seen advertisements for medications for heartburn or acid reflux? ( Yes I No
Jf yes, in which media formats have you seen these advertisements? (Check all that apply.)
magazines, newspapers
television
internet
radio
8. Do you recall the names of any of the med ications? (

Yes

I

No

)

)

1fyes, please list them:
9. Do you recall any detai ls (catchphrases, scenarios) of the advert isements? (
Jfyes, please list them:

10. Have you taken any medications for heartburn or acid reflux? (
Jfyes, please list them:

Yes

11 . Have you seen a physician for heartburn or acid reflux symptoms? (

I

Yes

I

No

)

Yes

I

No

12. Have you rece ived a prescription medication for heartburn or acid reflu x? (

Yes

No

)

)
I

No

13. How frequently do you use medications for heartburn or acid-reflux?
never
every 4-6 months
every 2-4 months
weekly
several times a week
every 1-2 months
14. Have advertisements for med ications influenced your approach to heartburn or acid reflux
symptoms? (Check a ll that apply.)
encouraged you to start using medication for heartburn/reflux
encouraged you to use your medicat ion more frequently
encouraged you to change your medication
increased your concern for a serious underlying medical condition
led you to see a doctor for heartburn/reflux symptoms
15. Do you smoke cigarettes? ( Yes
Jfyes, how many packs per day?

I

No

)

16. Do you drink alcohol? ( Yes I No )
ffyes, how frequently?
never __ 2-3 times a year _ _ 2-3 times a month __ 2-3 times a week __ daily
Thank you!

)

